February 19, 2019
Jennifer Barrett, Associate Editor
Potential adverse effects from health interventions, such as a drug reaction or an effect of a procedure, were not fully reported in more than one-third of published health study reviews.

LATEST NEWS

Jennifer Barrett, Associate Editor
Caplacizumab-yhdp treats adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting autoimmune disorder.  
Jennifer Barrett, Associate Editor
Pemetrexed plus pembrolizumab is indicated for use along with platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Cecilia Pessoa Gingerich
There is currently no rituximab biosimilar approved by the FDA for rheumatoid arthritis.
SPT Staff
Ontruzant (trastuzumab-dttb) is indicated for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.
Jennifer Barrett, Associate Editor
Crizanlizumab under evaluation for the prevention of vaso-occlusive crises in patients of all genotypes with sickle cell disease.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us